Table 3.
Subgroup Analysis between Patients in Remission and Patients with Active Disease
| Variable | UC (n=45) |
CD (n=42) |
||||
|---|---|---|---|---|---|---|
| Active disease (n=13) | In remission (n=32) | P-value | Active disease (n=14) | In remission (n=28) | P-value | |
| Disease duration (yr) | 3.9±4.9 | 7.4±5.8 | 0.282a | 2.8±2.7 | 3.0±2.3 | 0.679a |
| Medication | ||||||
| 5-ASA | 13 (100) | 32 (100) | >0.999b | 13 (92.9) | 28 (100) | 0.333b |
| Prednisolone | 8 (61.5) | 17 (53.1) | 0.745b | 12 (85.7) | 12 (42.9) | <0.05 |
| Immunomoulators (AZA/MTX/6-MP) | 9 (69.2) | 14 (43.8) | 0.189b | 11 (78.6) | 15 (53.6) | 0.180b |
| Anti-TNF (infliximab/adalimumab) | 7 (53.8) | 4 (12.5) | <0.05 | 8 (57.1) | 9 (32.1) | 0.184b |
| IBD-related surgery | 1 (7.7) | 1 (3.1) | 0.499b | 2 (14.3) | 1 (3.6) | 0.254b |
| Mean 25-OH vitamin D (ng/mL) | 13.0±8.4 | 18.7±9.9 | 0.361a | 9.6±2.9 | 18.3±8.5 | <0.05 |
| Vitamin D deficiency (<20 ng/mL) | 12 (92.3) | 21 (65.6) | 0.134b | 14 (100) | 17 (60.7) | <0.05 |
| Hemoglobin (g/dL) | 14.1±1.9 | 13.3±2.4 | 0.329a | 13.4±1.9 | 14.1±1.2 | 0.051a |
| WBC (×106 cells/μL) | 8.0±3.0 | 7.1±2.7 | 0.545a | 7.5±4.1 | 6.2±1.8 | <0.05 |
| ESR (mm/hr) | 32.2±31.3 | 17.3±19.1 | 0.169a | 33.9±32.4 | 24.6±18.0 | <0.05 |
| CRP (mg/dL) | 2.2±4.4 | 0.4±0.6 | <0.05 | 0.6±0.5 | 0.4±0.5 | 0.503a |
| Albumin (g/dL) | 4.3±0.3 | 4.3±0.4 | 0.989a | 4.1±0.9 | 4.4±0.2 | <0.05 |
| Total cholesterol (mg/dL) | 176.2±23.5 | 183.4±38.8 | 0.078a | 168.6±61.3 | 176.1±31.3 | 0.120a |
Values are presented as mean±SD or number (%).
a
Independent sample t-test.
b
Fisher exact test.
5-ASA, 5-aminosalicylic acid; AZA, azathioprine; MTX, methotrexate; 6-MP, 6-mercaptopurine; TNF, tumor necrosis factor; 25-OH vitamin D, 25-hydroxyvitamin D; WBC, white blood cells.